Receptor-interacting protein kinase-3 (RIPK3): a new biomarker for necrotising enterocolitis in preterm infants
link.springer.com shows its articles on its own site.
Read the article on link.springer.com ↗Article · May 2024 · 1 min read
In brief
In brief
This study identifies RIPK3 as a novel plasma biomarker for diagnosing necrotising enterocolitis in preterm infants, with superior performance when combined with lactic acid and CRP. RIPK3 levels correlate with disease severity and predict time to full enteral feeding post-recovery, offering clinicians a tool for both diagnosis and feeding management decisions.
- Plasma RIPK3 levels correlate with NEC severity in preterm infants, with stage III NEC showing mean levels of 32.37 ng/mL.
- Combined RIPK3, lactic acid, and CRP testing achieves 0.925 ROC AUC for NEC diagnosis, superior to individual markers.
- RIPK3 levels ≥20.06 ng/mL predict longer time to full enteral feeding post-NEC, guiding feeding advancement strategies.
- RIPK3 serves as a novel biomarker for both diagnostic and prognostic assessment in neonatal necrotizing enterocolitis.
- This multi-biomarker approach may enable earlier NEC detection and risk stratification in vulnerable preterm populations.
Written by the GCMD Library team from the article.
Abstract
Objective
This study aimed to evaluate the role of receptor-interacting protein kinase-3 (RIPK3) in the diagnosis, estimation of disease severity, and prognosis of premature infants with necrotising enterocolitis (NEC).
Methods
RIPK3, lactic acid (LA), and C-reactive protein (CRP) levels were measured in the peripheral blood of 108 premature infants between 2019 and 2023, including 24 with stage II NEC, 18 with stage III NEC and 66 controls. Diagnostic values of the indicators for NEC were evaluated via receiver operating characteristic (ROC) curve analysis.
Results
Plasma RIPK3 and LA levels upon NEC suspicion in neonates with stage III NEC were 32.37 ± 16.20 ng/mL. The ROC curve for the combination of RIPK3, LA, CRP for NEC diagnosis were 0.925. The time to full enteral feeding (FEFt) after recovery from NEC was different between two expression groups of plasma RIPK3 (RIPK3 < 20.06 ng/mL and RIPK3 ≥ 20.06 ng/mL).
Conclusion
Plasma RIPK3 can be used as a promising marker for the diagnosis and estimation of disease severity of premature infants with NEC and for the guidance on proper feeding strategies after recovery from NEC.